Clinical trial
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
NCT00183742 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00183742 |
|---|---|
| Title | Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) |
| Official title | Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Carcinoma |
| Intervention type | Drug |
| Interventions | liposomal doxorubicin and docetaxel |
| Enrollment | 35 |
| Start date | Dec 1, 2000 |
| Primary completion | Oct 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: